Recovery
Larazotide
Also called AT-1001, INN-202
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
The human evidence for Larazotide used the oral route. The draw worked out here assumes a subcutaneous injection, so the amount is not a direct read-across.
Quick start
Larazotide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.5–2 mg per administration
- How often
- Twice a day
- Where
- Oral
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Larazotide describe 0.5–2 mg per administration. Descriptive only, not a recommendation.
Acts locally in the gut with minimal systemic absorption, so a plasma half-life is not the relevant figure.
Taken by mouth and minimally absorbed, acting locally in the gut, so a subcutaneous draw does not apply and no schedule table is shown. The human evidence is oral (0.5–2 mg three times daily); the vial size shown is nominal.
Where these numbers come from
- Leffler DA et al., Gastroenterology 2015;148:1311Oral larazotide acetate at 0.5, 1 and 2 mg three times daily assessed in celiac disease; the 0.5 mg amount was carried forward.